New Fashion Design for Notoginseng Extract to Oman Manufacturers

New Fashion Design for
 Notoginseng Extract to Oman Manufacturers

Short Description:


Product Detail

Product Tags

We believe that prolonged expression partnership is really a result of top of the range, value added support, rich encounter and personal contact for Ginkgo Biloba Extract , Black Ginseng Extract , Alkaloid , We welcome new and outdated consumers from all walks of existence to speak to us for long run enterprise relationships and acquiring mutual success!
New Fashion Design for Notoginseng Extract to Oman Manufacturers Detail:

st


Product detail pictures:

New Fashion Design for
 Notoginseng Extract to Oman Manufacturers detail pictures


We provide fantastic power in excellent and growth,merchandising,revenue and promoting and operation for New Fashion Design for Notoginseng Extract to Oman Manufacturers, The product will supply to all over the world, such as: Lisbon , Estonia , Bogota , We insist on "Quality First, Reputation First and Customer First". We've been committed to providing high-quality items and good after-sales services. Up to now, our goods have been exported to more than 60 countries and areas around the world, such as America, Australia and Europe. We enjoy a high reputation at home and abroad. Always persisting in the principle of "Credit, Customer and Quality", we expect cooperation with people in all walks of life for mutual benefits.



  • Immunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX). This novel immunotherapy begins with a two injection procedure into any one accessible tumor, intended to liberate and utilize the patient’s tumor antigens to generate a systemic antitumor immune response.

    Immunophotonics was founded in 2009 to develop and commercialize GC (N-dihydro-galacto-chitosan), the proprietary immune-activating drug used in the inCVAX approach. The company synthesizes GC (N-dihydro-galacto-chitosan) as GMP-grade drug product for use in its clinical trials.

    First-in-human investigator driven clinical studies in stage III & IV metastatic breast cancer patients have been encouraging. As published in a peer-reviewed journal, several patients experienced shrinkage of both local tumors and distant metastases. In some cases, this led to a complete, long-term response. A randomized controlled trial to further assess the safety and efficacy of inCVAX is ongoing in South America. The company is currently preparing for the initiation of additional clinical trials in the United States and Europe.

    Send your message to us:

    INQUIRY NOW
    • * CAPTCHA: Please select the Tree

    Related Products

    INQUIRY NOW
    • * CAPTCHA: Please select the Flag

    WhatsApp Online Chat !